User Tools
ats_2026
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| ats_2026 [2025/11/05 15:20] – admin | ats_2026 [2025/11/05 17:50] (current) – admin | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ## Authors | ||
| - | Eric W. Robbins 1 | ||
| - | Jacqueline Robinson 2,3 | ||
| - | Emmanuel Robinson 4 | ||
| - | Yvonne Chung 2,3 | ||
| - | Erin Niles 5 | ||
| - | Kimberly Boswell 2,6 | ||
| - | Emily Esposito 2,6 | ||
| - | Daniel Haase 2,6 | ||
| - | Elizabeth Powell 2,6 | ||
| - | |||
| - | 1 Department of Medicine; Division of Pulmonary, Critical Care, and Sleep Medicine; University of Maryland School of Medicine; Baltimore, MD, USA | ||
| - | 2 Program in Trauma, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA | ||
| - | 3 Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA. | ||
| - | 4 Department of Surgery, Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD, USA | ||
| - | 5 Critical Care Resuscitation Unit, R Adams Cowley Shock Trauma Center, Baltimore, MD, USA | ||
| - | 6 Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. | ||
| - | |||
| - | ## Introduction | ||
| - | Status asthmaticus refractory to conventional therapy can lead to life-threatening respiratory failure. | ||
| - | Veno-venous extracorporeal membrane oxygenation (VV ECMO) is a potentially life-saving intervention for this population, but current literature is limited. | ||
| - | We hypothesized that patients with status asthmaticus who received VV ECMO would have favorable survival rates. | ||
| - | |||
| - | ## Methods | ||
| - | We performed a single-center retrospective review of adult patients (≥18 years) supported with VV ECMO for status asthmaticus between January 2014 and January 2025. | ||
| - | Patients were identified through our Lung Rescue Unit database. | ||
| - | Clinical characteristics, | ||
| - | The primary outcome was survival to hospital discharge. | ||
| - | |||
| - | ## Results | ||
| - | Fifteen patients met inclusion criteria (median age 32 years; 53% male). | ||
| - | The survival rates for status asthmaticus (86.7%; n=13/15) and our overall VV ECMO cohort (78.0%; n = 439/563) were not statistically significant (p = 0.42). | ||
| - | Survivors of status asthmaticus had longer hospital stays (16 vs 5 days, p=0.03) and were less likely to have had a cardiac arrest prior to ECMO initiation (7% vs 100%, p=0.03), compared to non-survivors. | ||
| - | Mean pre-cannulation pH was 7.08, and mean paCO2 was 81 mmHg. | ||
| - | Scoring systems suggested high expected survival: mean scores were RESP 3, SOFA 8, SAPS II 28, and PRESET 5. | ||
| - | Compared to the broader institutional VV ECMO cohort, status asthmaticus patients had shorter ECMO durations and lower tracheostomy rates (13% vs 15%, p=0.01). | ||
| - | |||
| - | ## Conclusions | ||
| - | VV ECMO is a viable therapy for patients with status asthmaticus refractory to conventional management, with our center' | ||
| - | Further research is needed to refine selection criteria and optimize outcomes in this population. | ||
| - | |||
| - | |||
| - | |||
| ====== Admin Details ====== | ====== Admin Details ====== | ||
ats_2026.1762356041.txt.gz · Last modified: by admin
Except where otherwise noted, content on this wiki is licensed under the following license: CC Attribution-Share Alike 4.0 International
